Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: Proposal for a new dosing regimen

International Journal of Laboratory Hematology

Volumn 34, Issue 5, 2012, Pages 517-524

  El Din, M S ^a   Amin, Dalia G ^a   Ragab, S B ^b   Ashour, E E ^b   Mohamed, M H ^c   Mohamed, A M ^c  

^a CAIRO UNIVERSITY   (Egypt)

^b Fayoum University   (Egypt)

^c NATIONAL HEART INSTITUTE   (Egypt)

Author keywords

CYP2C9; Real time PCR; VKORC1; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INDICATION; EGYPT; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEART VALVE PROSTHESIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE DRUG DOSE; MALE; PREVALENCE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; EGYPT; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; WARFARIN; YOUNG ADULT;

EID: 84865549975     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2012.01426.x     Document Type: Article

References (31)

1. Daly A, King B. Pharmacokinetics of oral anticoagulants. Pharmacogenetics 2003;13:247-52.
2. Rosemary J, Adithan C. The Pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol 2007;2:93-109.
3. McClain MR, Palomaki GE, Piper M, Haddow JE. A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med 2008;10:89-98.
4. Caldwell M, Berg R, Zhang K, Glurich I, Schmelzer J, Yale S, Vidaillet H, Burmester J. Evaluation of genetic factors for warfarin dose prediction. Clin Med Res 2007;5:8-16.
5. D'Andrea G, D'Ambrosio R, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose anticoagulant effect of warfarin. Blood 2005;105:645-9.
6. Yuan H, Chen J, Lee M, Wung J, Chen Y, Charng M, Lu MJ, Hung CR, Wei CY, Chen CH, Wu JY, Chen YT. A novel functional VKORC1 promoter polymorphism is associated with interindividual and interethnic differences in warfarin sensitivity. Hum Mol Genet 2005;14:1745-51.
7. Francis C. New issues in oral anticoagulants. Am Soc Hematol 2008;25:260-4.
8. Yin T, Miyata T. Warfarin dose and the pharmacogenomics next term of CYP2C9 and VKORC1-rationale and perspectives. Thromb Res 2007;120:1-10.
9. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009;113:784-92.
10. Kangelaris K, Bent S, Nussbaum R, Garcia D, Tice J. A systematic review of pharmacogenetic dosing of warfarin. Genetic testing before anticoagulation?. J Gen Intern Med 2009;24:656-64.
11. Huang S, Li Q, Zu S, Li L, Xiong F, Jia Y, Xu X. SYBR Green-based real time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement. Clin Chem Lab Med 2009;47:26-31.
12. Funk M, Endler G, Freitag R, Wojta J, Huber K, Mannhalter C, Sunder-Plassmann R. CYP2C9*2 and CYP2C9*3 alleles confer a lower risk for myocardial infarction. Clin Chem 2004;50:2395-8.
13. Olivier C. Rheumatic fever - is it still a problem. J Antimicrob Chemother 2000;45:13-21.
14. Kimura R, Miyashida K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, Otsuki T, Okayama A, Minematsu K, Naritomi H, Honda S, Tomoike H, Miyata T. Genotypes of vitamin K epoxide reductase, γ-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 2007;120:181-6.
15. Limdi N, Mc Gwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on Warfarin. Clin Pharmacol Ther 2008;83:312-21.
16. Yang J, Huang C, Shen Z, Miao L. Contribution of 1173C>T polymorphism in the VKORC1 gene to warfarin dose requirements in Han Chinese patients receiving anticoagulation. Int J Clin Pharmacol Ther 2011;49:23-9.
17. Hamdy S, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed M, Mizugaki M. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 2002;53:596-603.
18. Tanira M, Al-Mukhaini M, Al-Hinai A, Al Balushi K, Ahmed I. Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose. Commun Genet 2007;10:32-7.
19. Higashi M, Veenstra D, Kondo L, Wittkowsky A, Srinouanprachanh S, Farin F, Rettie A. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. J Am Med Assoc 2002;287:1690-8.
20. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000;96:1816-9.
21. Yoon Y, Shon J, Kim M, Lim Y, Lee H, Park J, Cha IJ, Shin JG. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 2001;51:277-80.
22. Zainuddin Z, Teh L, Suhaimi A, Ismail R. Malaysian Indians are genetically similar to Caucasians: CYP2C9 polymorphism. J Clin Pharmacol Ther 2006;31:187-91.
23. Lee C, Goldstein J, Pieper J. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002;12:251-63.
24. D'Andrea G, D'Ambrosio R, Margaglione M. Oral anticoagulants: pharmacogenetics relationship between genetic and nongenetic factors. Blood Rev 2008;22:127-40.
25. Mushiroda T, Ohnishi Y, Saito S, Takahashi A, Kikuchi Y, Saito S, Shimomura H, Wanibuchi Y, Suzuki T, Kamatani N, Nakamura Y. Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J Hum Genet 2006;51:249-53.
26. Stehle S, Kirchheiner J, Lazar A, Fuhr U. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet 2008;47:565-94.
27. Bodin L, Verstuyft C, Tregouet D, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, Loriot MA. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005;106:135-40.
28. Veenstra DL, You JH, Rieder MJ, Farin FM, Wilkerson HW, Blough DK, Cheng G, Rettie AE. Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 2005;15:687-91.
29. Sipeky C, Lakner L, Szabo M, Takacs I, Tamasi V, Polgar N, Falus A, Melegh B. Interethnic differences of CYP2C9 alleles in healthy Hungarian and Roma population samples: relationship to worldwide allelic frequencies. Blood Cell Mol Dis 2009;43:239-42.
30. Aynacioglu S, Brockmoller J, Bauer S, Sachse C, Güzelbey P, Öngen Z, Nacak M, Roots I. Frequency of cytochrome P4502C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999;48:409-15.
31. Namazi S, Azarpira N, Hendijani F, Khorshid MB, Vessal G, Mehdipour AR. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran. Clin Ther 2010;32:1050-60.